OakChart

Grace Therapeutics Inc

GRCEHealthcare·Biotechnology·USA·Nano·NASD·Nov 12 • 3:58 PM ET

1.81-0.04 (-2.43%)
2026-11-13 06:16 CET
Market cap
$38.07M
Revenue, TTM
0.00 USD m
Net income, TTM
-20.22 USD m
Free cash flow, TTM
-10.36 USD m
EPS diluted, TTM
-1.18
Price / earnings
-
Compare

Price

GRCE against its 20, 50 and 200-day averages
Terms2050200BeatMissEarnings
Patternshover a marker to name it
RS 0Sales 0.00Price0.002.002.503.003.50678K1.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26GRCEclose 1.8120-day 1.8850-day 2.02200-day 2.731.8152w low

65.1% under the 52-week high of 5.18 on 2 Apr 2026. 52-week low 1.67 on 26 Oct 2026. Last 15 sessions, 22.6% high to low

Volume 0.67× normal · the line is the 50-bar volume average

Setup. RS line 0
CANSLIM 0 of 6 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); 52-Week High/Low: 0-10% below High; Performance: Year +50%; Institutional Ownership: Over 50%; Average Volume: Over 200K
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 0 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; Average Volume: Over 500K; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 1 of 4 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); Return on Equity: Over +15%
Quality 2 of 5 — fails: Return on Equity: Over +15% — not on the tape: Net Profit Margin: High (>20%); P/E: Under 25
Value 2 of 4 — fails: Return on Equity: Over +15% — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 1 of 4 — fails: Average Volume: Over 500K; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 1 of 4 — fails: Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 0 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200; Average Volume: Over 500K

Profile

GRCE
52-week range, 4% of the way up
1.675.18

Grace Therapeutics, Inc. engages in the development and commercialization of drug candidates for rare and orphan diseases. It focuses on utilizing proprietary technologies to improve the performance of currently marketed drugs. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Princeton, NJ.

Employees5
IPOMay 06, 2011
Beta0.41
ATR, 14d0.13
Rel volume0.67
Short float9.75%
Insider own18.68%
Inst own32.93%

Snapshot

6 groups

Valuation

Index-
Market Cap$38.07M
Enterprise Value24.31M
Income-20.22M
Sales0.00M
Book / share2.96
Cash / share0.65
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees5
IPOMay 06, 2011

Ratios

Price / earnings-
Forward price / earnings-
Price / earnings / growth-
Price / sales-
Price / book0.61
Price / cash2.77
Price / free cash flow-
Value / cash profit-
Value / sales-
Quick Ratio11.47
Current Ratio11.47
Debt / equity0.00
Long-term debt / equity0.00
Options and shortYes / Yes

Earnings

Earnings / share-1.18
Earnings next year-0.47
Earnings next quarter-0.15
Earnings this year-43.62%
Earnings next year31.11%
Earnings growth, 5 years-
Past earnings growth56.43% 43.17%
Past sales growth- -
Earnings vs last year-43.60%
Sales vs last year-
Earnings vs last quarter-333.11%
Sales vs last quarter-
EarningsNov 12 BMO
Surprise26.67% -

Ownership

Insiders own18.68%
Insider trades11.54%
Institutions own32.93%
Institution trades-4.49%
Return on assets-33.74%
Return on equity-36.19%
Return on capital-41.94%
Gross Margin-
Operating margin-
Profit Margin-
20-day average-3.76%
50-day average-10.24%
200-day average-33.81%

Technical

Shares out21.04M
Shares floating17.11M
Short / float9.75%
Short ratio13.15
Short interest1.67M
52-week high5.18 -65.1%
52-week low1.67 +8.4%
Volatility4.79% 7.73%
Average range0.13
Strength index41.00
Market sensitivity0.41
Relative volume0.67
Avg Volume126.77K
Volume85,183

Performance

Perf Week1.69%
Perf Month-4.23%
Perf Quarter-16.20%
Perf Half Y-17.35%
Perf YTD-47.69%
Perf Year-40.26%
Perf 3Y-18.60%
Perf 5Y-81.38%
Perf 10Y-97.27%
Recommendation1.00
Target Price6.00
Prev Close1.86
Price1.81
Change %-2.43%

Analyst ratings

latest 7 of 7
DateActionAnalystRating changeTargetImplied
May 02, 2025InitiatedTD CowenBuy$12+563.0%
Sep 01, 2020DowngradeOppenheimerOutperform → Perform
Jul 06, 2020UpgradeB. Riley FBRNeutral → Buy$2+10.5%
Jan 13, 2020DowngradeB. Riley FBRBuy → Neutral
Aug 29, 2019InitiatedB. Riley FBRBuy$7.75+328.2%
Jul 18, 2019InitiatedOppenheimerOutperform$7+286.7%
Jun 26, 2019InitiatedH.C. WainwrightBuy$6+231.5%

Peers

Mkt cap
TickerCompanyMkt cap
MISTMilestone Pharmaceuticals Inc81.57M
DMACDiaMedica Therapeutics Inc503.12M
TENXTenax Therapeutics Inc73.32M
HRTXHeron Therapeutics Inc62.01M
CVKDCadrenal Therapeutics Inc5.38M
CALCCalciMedica Inc8.41M
ICUSeaStar Medical Holding Corp5.58M
UNCYUnicycive Therapeutics Inc101.39M
ZVRAZevra Therapeutics Inc664.07M
PCSAProcessa Pharmaceuticals Inc5.15M

Insider trading

latest 14 of 22
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Opaleye Management Inc.10% OwnerNov 03 '26Buy1.7910,32818,4813,046,739Nov 05 09:05 PM
Opaleye Management Inc.10% OwnerNov 04 '26Buy1.805,0279,0603,051,766Nov 05 09:05 PM
Opaleye Management Inc.10% OwnerNov 05 '26Buy1.773,0875,4783,054,853Nov 05 09:05 PM
Opaleye Management Inc.10% OwnerOct 26 '26Buy1.7766,411117,4083,036,411Oct 26 06:06 PM
Opaleye Management Inc.10% OwnerOct 22 '26Buy1.9321,39041,1932,970,000Oct 26 06:06 PM
Opaleye Management Inc.10% OwnerOct 19 '26Buy1.884,2568,0012,948,610Oct 21 06:06 PM
Opaleye Management Inc.10% OwnerOct 16 '26Buy1.8936,34768,7582,944,354Oct 16 08:42 PM
Opaleye Management Inc.10% OwnerOct 15 '26Buy1.9523,48545,6852,908,007Oct 16 08:42 PM
Opaleye Management Inc.10% OwnerOct 14 '26Buy1.9311,23321,7352,884,522Oct 16 08:42 PM
Opaleye Management Inc.10% OwnerOct 12 '26Buy2.027,21514,5742,873,289Oct 13 05:45 PM
Opaleye Management Inc.10% OwnerOct 09 '26Buy2.045,34010,9182,866,074Oct 13 05:45 PM
Opaleye Management Inc.10% OwnerOct 08 '26Buy2.022,0774,1902,860,734Oct 13 05:45 PM
Opaleye Management Inc.10% OwnerOct 01 '26Buy2.0438,79678,9612,836,963Oct 05 06:46 PM
Opaleye Management Inc.10% OwnerOct 02 '26Buy2.0720,00041,3682,856,963Oct 05 06:46 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 696.31B
IWCiShares Micro-Cap ETFAUM: 1.23B

News

latest 14 of 200
  • Grace Therapeutics Announces Second Quarter 2027 Financial Results, Provides Business Update (GlobeNewswire)
  • Grace: Fiscal Q2 Earnings Snapshot (Associated Press)
  • Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026 (GlobeNewswire)
  • Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference (GlobeNewswire)
  • Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update (GlobeNewswire)
  • Grace Therapeutics Announces $10 Million Private Placement (GlobeNewswire)
  • Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration (GlobeNewswire)
  • Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update (GlobeNewswire) +7.21%
  • Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104 (GlobeNewswire) -45.48%
  • Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026 (GlobeNewswire) +12.04%
  • Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences (GlobeNewswire)
  • Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
  • Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update (GlobeNewswire)
  • Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-11-12-0.110-0.150-0.1500.000.001
2026Q12026-08-13-0.910-0.129-0.9100.000.001
2025Q42026-06-18-0.060-0.230-0.0740.000.002
2025Q32026-02-12-0.140-0.280-0.1370.000.001
2025Q22025-11-13-0.060-0.251-0.0590.000.001
2025Q12025-08-12-0.210-0.220-0.2110.000.001
2024Q42025-06-230.110-0.2780.0460.000.004
2024Q32025-02-13-0.360-0.335-0.3610.000.002
2024Q22024-11-13-0.300-0.370-0.2980.000.003
2024Q12024-08-09-0.240-0.265-0.2400.000.002
2023Q42024-06-21-0.170-0.350-0.3370.000.001
2023Q32024-02-12-0.210-0.230-0.2080.000.001
2023Q22023-11-13-0.430-0.260-0.4330.000.001
2023Q12023-08-11-0.540-0.280-0.5410.000.001
2022Q42023-06-23-3.900-0.840-3.9120.000.001
2022Q32023-02-14-0.540-0.740-0.5230.000.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-34.702-23.376-34.8050.000.00
2019FY-14.400-25.731-14.4790.000.00
2020FY-8.160--7.9620.20-
2021FY-1.620-0.840-1.599--
2022FY-5.700-2.640-5.7060.00-
2023FY-1.350-1.440-1.3490.000.00
2024FY-0.790-1.163-0.7920.000.00
2025FY-0.470-0.825-0.4700.000.00
2026FY--0.675--0.00
2027FY--0.465--5.00
2028FY-1.600--100
2029FY-2.400--140

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-11-121000.000.000.00
2026Q3S2026-08-131000.000.000.00
2026Q3S2026-07-071000.000.000.00
2026Q3S2026-06-181010.000.000.00
2026Q3S2026-04-231010.000.000.00
2026Q3S2026-02-121012.302.302.30
2026Q3S2025-11-131002.652.652.65
2026Q3S2025-11-121002.652.652.65
2026Q3R2026-11-12100-0.15-0.15-0.15
2026Q3R2026-10-31100-0.15-0.15-0.15
2026Q3R2026-08-17101-0.15-0.15-0.15
2026Q3R2026-08-13110-0.13-0.13-0.13
2026Q3R2026-06-18110-0.13-0.13-0.13
2026Q3R2026-04-23110-0.15-0.15-0.15

Estimate history

EPS, annual-45.979-34.805-14.479-7.962-1.599-5.706-1.349-0.792-0.472-1.1834
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.24-0.298-0.3610.046-0.211-0.059-0.137-0.074-0.914
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Sales, annual0000.196000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Shares, annual0.5341.6281.8794.3417.3817.4359.39913.71816.02416.274
Period201720182019202020212022202320242025MRQ
Shares, quarterly10.1410.1410.1413.71813.82914.12915.47416.02416.274
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.200.000.00
Cost of Goods Sold Incl. D&A0.010.010.010.010.120.001.002.322.33
Gross Profit-0.01-0.01-0.01-0.01-0.120.00-0.80-2.32-2.33
Selling, General and Administrative Excl. Other10.3711.0716.6711.3018.2915.9210.0422.4331.78
Research and Development2.152.419.514.6310.146.143.3813.9727.49
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-10.37-11.08-16.68-11.31-18.41-15.92-10.84-24.75-34.11
Interest Expense0.000.000.000.000.000.000.260.290.79
Unusual Expense12.15-0.90-3.224.2133.90-4.958.131.125.49
Net Income Before Taxes-21.92-9.49-12.77-14.63-52.14-11.04-19.81-25.83-39.81
Income Taxes-1.70-1.70-3.20-1.78-9.71-1.23-0.13-0.31-0.45
Consolidated Net Income-20.22-7.79-9.57-12.85-42.43-9.82-19.68-25.51-39.37
Net Income From Continuing Operations-20.22-7.79-9.57-12.85-42.43-9.82-19.68-25.51-39.37
Net Income-20.22-7.79-9.57-12.85-42.43-9.82-19.68-25.51-39.37
EPS (Recurring)-0.68-0.51-0.98-1.04-2.52-2.16-5.66-14.04-31.41
EPS (Basic, Before Extraordinaries)-1.18-0.47-0.79-1.35-5.71-1.60-7.96-14.48-34.80
EPS (Diluted)-1.18-0.47-0.79-1.35-5.71-1.60-7.96-14.48-34.80
EBITDA-10.37-11.07-16.67-11.30-18.29-15.92-9.92-22.43-31.78
Non-Operating Income (Expense)0.600.680.690.900.17-0.07-0.570.330.57
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.600.630.580.721.431.341.171.950.78
Price To Sales Ratio------363.14--
Gross Margin-------410.20--
Operating Margin-------5,532.14--
Net Margin-------10,039.80--
Shares Outstanding16.2716.0213.729.407.447.384.341.881.63
Market Capitalization38.0838.0831.2831.83-----

Income statement, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q2
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit-0.00-0.00-0.000.00-0.00-0.00-0.00-0.00
Selling, General and Administrative Excl. Other2.383.012.452.533.093.183.704.83
Research and Development0.700.420.460.570.961.632.192.98
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.38-3.01-2.45-2.53-3.09-3.18-3.70-4.83
Interest Expense0.000.000.000.000.000.00-0.00
Unusual Expense13.530.000.04-1.430.49-2.641.18-0.36
Net Income Before Taxes-15.79-2.88-2.32-0.94-3.36-0.38-4.76-4.28
Income Taxes0.00-1.700.000.000.00-1.02-0.61-0.85
Consolidated Net Income-15.79-1.18-2.32-0.94-3.360.64-4.16-3.43
Net Income From Continuing Operations-15.79-1.18-2.32-0.94-3.360.64-4.16-3.43
Net Income-15.79-1.18-2.32-0.94-3.360.64-4.16-3.43
EPS (Recurring)-0.37-0.07-0.14-0.12-0.19-0.09-0.29-0.32
EPS (Basic, Before Extraordinaries)-0.91-0.07-0.14-0.06-0.210.05-0.36-0.30
EPS (Diluted)-0.91-0.07-0.14-0.06-0.210.05-0.36-0.30
EBITDA-2.38-3.01-2.45-2.53-3.09-3.18-3.70-4.83
Non-Operating Income (Expense)0.130.130.170.160.220.160.120.19
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.110.180.110.210.300.100.130.16
Shares Outstanding16.2716.0215.4714.1313.8313.7210.1410.14
Market Capitalization38.0871.6453.5441.1741.0731.2837.9239.04

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments16.9822.1323.0027.8943.6660.7314.2425.766.38
Short Term Receivables0.020.130.720.800.550.530.551.190.59
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.380.450.280.601.321.111.170.880.40
Total Current Assets17.3822.7124.0129.2945.5362.3715.9627.837.36
Net Property, Plant & Equipment0.010.010.020.570.320.092.062.112.19
Total Investments and Advances0.000.000.000.000.000.000.000.020.02
Intangible Assets49.2749.2749.2749.2782.770.004.246.397.81
Deferred Tax Assets10.959.25-------
Other Assets0.000.000.000.000.000.000.590.550.43
Total Assets77.6081.2473.3079.12128.6262.4622.8536.9017.81
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.070.100.090.081.360.00
Accounts Payable0.700.601.011.241.680.120.000.002.65
Other Current Liabilities1.441.330.682.091.481.387.3212.312.54
Total Current Liabilities2.151.931.683.413.261.587.3913.675.19
Long Term Debt0.000.000.000.410.190.000.070.001.25
Provision for Risks Charges0.000.000.000.000.000.000.000.00-
Deferred Tax Liabilities11.5611.565.517.3516.89----
Other Liabilities0.001.144.360.000.015.222.3912.184.98
Total Liabilities13.7114.6311.5611.1720.356.809.8625.8511.43
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity63.9066.6161.7467.95108.2755.6612.9911.046.38
Total Shareholders Equity63.9066.6161.7467.95108.2755.6612.9911.046.38
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity63.9066.6161.7467.95108.2755.6612.9911.046.38
Total Liabilities & Stockholders Equity77.6081.2473.3079.12128.6262.4622.8536.9017.81
Book Value Per Share3.994.866.579.1414.6712.826.916.7911.94
Tangible Book Value Per Share0.911.261.332.513.4512.824.662.86-2.67
Full-Time Employees5-4------
Price to Book Ratio0.610.440.45------
Return on Assets-9.81-12.38-16.86-40.85-10.28-46.13-86.29-143.92-90.78
Return on Equity-11.94-14.91-19.82-48.15-11.98-57.33-217.64-451.86-147.86
Return on Invested Capital-12.20-14.36-20.82-62.06-9.05-35.35-195.28-356.41-219.51
Quick Ratio8.1011.7714.268.5913.9739.502.162.041.42
Current Ratio8.1011.7714.268.5913.9739.502.162.041.42

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-20.28-7.79-9.57-12.85-42.43-9.82-19.68-25.51-39.37
Depreciation0.010.010.010.010.120.000.922.322.33
Other Funds (Non Cash)12.75-0.10-2.491.7926.21-4.6310.413.245.95
Funds from Operations-9.24-9.59-15.25-11.05-16.09-14.45-8.35-19.95-31.08
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1.120.720.34-1.280.18-2.79-5.97-2.996.29
Cash from Operating Activities-10.36-8.87-14.90-12.33-15.91-17.23-14.32-22.94-24.79
Capital Expenditures0.000.000.00-0.02-0.020.00-0.07-0.32-0.53
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.110.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.0213.17-3.52-9.798.46-8.91
Purchase of Investments0.000.00-0.02-6.55-5.02-34.93-9.81-1.92-18.85
Sale Or Maturity of Investments0.000.000.026.5718.1931.410.0210.389.94
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.1013.15-3.52-9.868.14-9.44
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock4.073.7114.037.360.300.0059.6314.7345.69
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock4.073.7114.037.360.300.0059.6314.7345.69
Proceedsfrom Stock Options-0.00-0.33-0.970.000.300.0059.336.9844.89
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.00-1.560.00
Change in Long Term Debt0.000.000.000.000.000.000.00-1.560.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.00-1.560.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00-0.140.000.00
Other Financing Activities Uses0.000.000.000.000.000.00-0.140.000.00
Cash from Financing Activities4.073.7114.037.360.300.0059.4913.1845.69
Exchange Rate Effect---0.00-0.010.151.39-1.00-1.01
Net Change in Cash-6.29-5.16-0.87-4.87-2.46-20.6036.70-2.6310.45
Free Cash Flow-10.36-8.87-14.90-12.36-15.93-17.23-14.39-23.26-25.32
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit--1.70-3.200.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q4
Cash & Short Term Investments13.7616.9818.6716.8620.0022.13
Short Term Receivables0.020.020.020.020.020.13
Inventories0.000.000.000.000.000.00
Other Current Assets0.560.380.520.420.500.45
Total Current Assets14.3317.3819.2117.3020.5222.71
Net Property, Plant & Equipment0.010.010.010.010.010.01
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets35.7349.2749.2749.2749.2749.27
Deferred Tax Assets-10.95---9.25
Other Assets0.000.000.000.000.000.00
Total Assets50.0777.6068.4966.5869.8181.24
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable0.410.700.110.461.340.60
Other Current Liabilities0.841.441.170.790.981.33
Total Current Liabilities1.252.151.281.252.311.93
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities0.6111.562.312.312.3111.56
Other Liabilities0.000.000.000.201.631.14
Total Liabilities1.8613.713.603.766.2514.63
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity48.2163.9064.8962.8263.5566.61
Total Shareholders Equity48.2163.9064.8962.8263.5566.61
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity48.2163.9064.8962.8263.5566.61
Total Liabilities & Stockholders Equity50.0777.6068.4966.5869.8181.24
Book Value Per Share2.963.994.194.454.604.86
Tangible Book Value Per Share0.770.911.010.961.031.26
Full-Time Employees-5----
Price to Book Ratio0.611.100.780.650.610.44
Return on Assets-33.74-9.81-9.22-11.85-14.78-12.38
Return on Equity-36.19-11.94-10.22-13.15-16.78-14.91
Return on Invested Capital-32.75-1.84-3.57-1.49-5.290.95
Quick Ratio11.478.1014.9613.898.8711.77
Current Ratio11.478.1014.9613.898.8711.77

Cash flow, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q4
Net Income-15.79-1.28-2.26-0.95-3.360.77
Depreciation0.000.000.000.000.000.00
Other Funds (Non Cash)13.640.180.15-1.220.79-0.28
Funds from Operations-2.15-2.81-2.11-2.17-2.57-2.61
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.071.00-0.06-0.980.77-0.07
Cash from Operating Activities-3.22-1.81-2.17-3.16-1.80-2.68
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.00-0.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.054.02-0.00-0.3313.60
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.054.02-0.00-0.3313.60
Proceedsfrom Stock Options0.00-0.000.00-0.00-0.33-0.94
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.000.054.02-0.00-0.3313.60
Net Change in Cash-3.22-1.761.85-3.16-2.1310.92
Free Cash Flow-3.22-1.81-2.17-3.16-1.80-2.68

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-309.75%1.7M17.1M139.31K
2026-10-159.84%1.7M17.1M165.82K
2026-09-3010.06%1.7M17.1M177.55K
2026-09-1510.32%1.8M17.1M218.27K
2026-08-319.22%1.6M17.2M229.70K
2026-08-1410.09%1.6M16.1M265.42K
2026-07-3112.81%1.6M12.4M311.33K
2026-07-1513.54%1.6M12.1M540.36K
2026-06-3014.41%1.7M11.8M717.92K
2026-06-1516.91%1.9M11.3M741.96K
2026-05-2917.91%2.0M11.3M782.07K
2026-05-1518.65%2.1M11.3M766.53K
2026-04-3019.48%2.2M11.3M702.57K
2026-04-1517.26%1.9M11.3M446.09K
2026-03-3114.64%1.7M11.3M258.70K
2026-03-1313.87%1.6M11.3M171.26K
2026-02-273.46%0.4M11.3M100.80K
2026-02-130.58%0.1M11.3M82.74K
2026-01-300.34%0.0M11.3M80.96K
2026-01-150.38%0.0M11.3M76.47K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.050.032.5942,7210.000.276-0.0150.001
call5.000.000.050.104.1247950.000.111-0.0130.001
call7.500.004.900.235.44811.000.000.095-0.0160.000
put2.500.350.800.702.86611410.00-0.813-0.0090.001
put5.000.605.002.827.75220.000.00-0.888-0.0140.001
put7.503.007.400.0030.3120.000.00-0.904-0.0150.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-128-KCurrent report2026-11-12SEC
2026-11-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-054Statement of changes in beneficial ownership of securities2026-11-03SEC
2026-10-264Statement of changes in beneficial ownership of securities2026-10-22SEC
2026-10-214Statement of changes in beneficial ownership of securities2026-10-19SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-10-14SEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-08SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-014Statement of changes in beneficial ownership of securities2026-09-29SEC
2026-10-014/A2026-09-21SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-09-188-KCurrent report2026-09-17SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-08-28SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-08-28SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-08-28SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-08-28SEC
2026-08-24S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-11DNotice of sales of securities on Form D (Regulation D)SEC
2026-08-07SCHEDULE 13GSEC
2026-08-068-KCurrent report2026-08-04SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-1133.02K300
2026-10456.28K1200
2026-09293.99K600
2026-0824.21K100
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Cerity Partners LLC5.22%
Eversept Partners, LP4.75%
BANK OF AMERICA CORP /DE/3.04%
VANGUARD CAPITAL MANAGEMENT LLC2.53%
CITADEL ADVISORS LLC2.15%
CANTOR FITZGERALD, L. P.1.23%
Maven Securities LTD1.23%
RENAISSANCE TECHNOLOGIES LLC0.88%
Birchview Capital, LP0.74%
TWO SIGMA INVESTMENTS, LP0.60%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.46%
iShares Micro-Cap ETF0.22%
TIFF MULTI-ASSET FUND0.10%
VANGUARD BALANCED INDEX FUND0.07%
Fidelity Nasdaq Composite Index Fund0.02%
1290 VT Micro Cap Portfolio0.01%

OakChart. GRCE. Cached 15 minutes. Terms